Plain-English translation of NCT06769659 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested , an experimental medication designed to reduce absence seizures in people with genetic generalized epilepsy. Researchers compared how well the medication worked against placebo (a inactive pill) by measuring the frequency and length of seizures detected on brain wave tests. The study included two different dose strengths to see which worked best.
Absence seizures can be difficult to control with existing medications, and many people still experience frequent seizures even while taking current treatments. This trial was designed to see whether this new medication could offer better seizure control for patients with genetic generalized epilepsy.
Participants received the medication (or placebo) twice daily by mouth for one treatment period, then stopped for 14 days, and then received the other treatment for a second period—without knowing which was the real medication and which was placebo. During the study, participants had brain wave tests (EEG) to measure how their seizures changed, attended clinic visits for check-ups, and completed laboratory tests to ensure safety.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States